CD274 and head and neck squamous cell carcinoma: Moreover, a phase II clinical trial evaluating anti-PD-L1 CAR-NK cells together with an immune check point inhibitor for the treatment of advanced HNSCC is currently recruiting (clinical trials.gov NCT04847466).